<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04305795</url>
  </required_header>
  <id_info>
    <org_study_id>ASP-1929-181</org_study_id>
    <nct_id>NCT04305795</nct_id>
  </id_info>
  <brief_title>An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors</brief_title>
  <official_title>An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rakuten Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rakuten Medical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label study using ASP-1929 photoimmunotherapy in combination with anti-PD1 therapy in&#xD;
      patients with recurrent or metastatic head and neck and squamous cell cancer or advanced or&#xD;
      metastatic cutaneous squamous cell carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cohorts of patients with recurrent or metastatic (R/M) squamous cell cancer of the head and&#xD;
      neck (HNSCC) or advanced or metastatic cutaneous squamous cell carcinoma will receive&#xD;
      anti-PD1 therapy in combination with anti EGFR antibody-dye conjugate, ASP-1929, followed by&#xD;
      photoimmunotherapy (PIT). HNSCC patients are required to have positive expression of&#xD;
      programmed cell death ligand 1 (PD-L1) defined by Combined Positive Score (CPS) ≥1. Primary&#xD;
      endpoints are safety, tolerability, and tumor response of ASP-1929 PIT treatment in&#xD;
      combination with anti-PD1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2020</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Characterize the safety and tolerability of ASP-1929 PIT treatment in combination with anti-PD1 therapy</measure>
    <time_frame>24 months</time_frame>
    <description>Treatment Emergent Adverse Events (TEAE) and Serious TEAE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HNSCC: Assess the effect of ASP-1929 PIT treatment with anti-PD1 therapy on tumor response</measure>
    <time_frame>24 months</time_frame>
    <description>Objective Response Rate (ORR) per modified RECIST 1.1, as assessed by investigator</description>
  </primary_outcome>
  <primary_outcome>
    <measure>cuSCC: Assess the effect of ASP-1929 PIT treatment with anti-PD1 therapy on tumor response</measure>
    <time_frame>24 months</time_frame>
    <description>Objective Response Rate (ORR) per modified RECIST 1.1, by central review</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>24 months</time_frame>
    <description>Assess the effect of ASP-1929 PIT treatment in combination with anti-PD1 therapy on survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>24 months</time_frame>
    <description>Assess the effect of ASP-1929 PIT treatment in combination with anti-PD1 therapy on survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>24 months</time_frame>
    <description>Assess the effect of ASP-1929 PIT treatment in combination with anti-PD1 therapy on survival</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Recurrent Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Metastatic Head-and-neck Squamous-cell Carcinoma</condition>
  <condition>Locally Advanced Cutaneous Squamous Cell Carcinoma</condition>
  <condition>Metastatic Cutaneous Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Cohort 1L- HNSCC</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Recurrent locally advanced and/or metastatic head and neck squamous cell carcinoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2- 1LcuSCC</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Locally advanced or metastatic cutaneous squamous cell carcinoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3- 2L CuSCC</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Locally advanced or metastatic cutaneous squamous cell carcinoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>200 mg Pembrolizumab</intervention_name>
    <description>IV on Day 1 of each 3-week cycle for up to 24 months</description>
    <arm_group_label>Cohort 1L- HNSCC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cemiplimab 350mg</intervention_name>
    <description>Photoimmunotherapy Light Treatment</description>
    <arm_group_label>Cohort 2- 1LcuSCC</arm_group_label>
    <arm_group_label>Cohort 3- 2L CuSCC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>ASP-1929</intervention_name>
    <description>IV on Day 1 of each 3-week cycle for up to 24 months</description>
    <arm_group_label>Cohort 1L- HNSCC</arm_group_label>
    <arm_group_label>Cohort 2- 1LcuSCC</arm_group_label>
    <arm_group_label>Cohort 3- 2L CuSCC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Overall Inclusion Criteria:&#xD;
&#xD;
        Provide written informed consent&#xD;
&#xD;
        • Cancers as follows:&#xD;
&#xD;
        Cohort 1 : Histologically or cytologically confirmed recurrent locally and/or metastatic&#xD;
        head and neck squamous cell carcinoma with Combined Positive Score (CPS) ≥ 1 as determined&#xD;
        by an FDA approved test&#xD;
&#xD;
        Note: A multi-disciplinary group (including a surgeon and radiation oncologist) must agree&#xD;
        that the patient is not a candidate for locoregional therapy.&#xD;
&#xD;
        Cohort 2 : Histologically or cytologically confirmed locally advanced or metastatic&#xD;
        cutaneous squamous cell carcinoma not amenable to definitive surgery or radiation.&#xD;
&#xD;
        Cohort 3: Histologically or cytologically confirmed locally advanced or metastatic&#xD;
        cutaneous squamous cell carcinoma not amendable to definitive surgery or radiation.&#xD;
        Patients' disease has progressed despite at least 2 months of anti-PD1 therapy.&#xD;
&#xD;
          -  At least one site of disease accessible to light illumination&#xD;
&#xD;
          -  Measurable disease by modified RECIST 1.1&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  No prior systemic therapy administered in the recurrent and/or metastatic setting&#xD;
             (with the exception of systemic therapy completed ≥ 6 months prior if given as part of&#xD;
             multimodal treatment for locally advanced disease)&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  Female patients of childbearing potential must have a negative pregnancy test at&#xD;
             screening and must be willing to use 2 methods of highly effective birth control while&#xD;
             on study or be surgically sterile, or abstain from heterosexual sexual activity for&#xD;
             the course of the study through 120 days after the last dose of anti-PD1 treatment.&#xD;
&#xD;
          -  Male participants must agree to use a highly effective method of contraception&#xD;
             starting with the first dose of study medication through 120 days after the last dose&#xD;
             of anti-PD1 treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior therapy with an anti-PD1 or anti-PD-L1 (Cohort 1 and 2 only)&#xD;
&#xD;
          -  Radiation therapy (or other non-systemic therapy) within 4 weeks prior to study Day 1&#xD;
             or not fully recovered from adverse events due to a previously administered treatment&#xD;
&#xD;
          -  Receiving chronic systemic steroid therapy (in doses exceeding 10 mg daily of&#xD;
             prednisone equivalent) or any other form of immunosuppressive therapy within 14 days&#xD;
             prior to Cycle 1 Day 1.&#xD;
&#xD;
          -  Diagnosed and/or treated for additional malignancy within 2 years prior to study Day&#xD;
             1, except for, curatively treated basal cell carcinoma of the skin, squamous cell&#xD;
             carcinoma of the skin and/or curatively resected in situ cervical and/or breast&#xD;
             cancers&#xD;
&#xD;
          -  History of significant (≥ Grade 3) cetuximab infusion reactions&#xD;
&#xD;
          -  Prior allogeneic tissue/solid organ transplant&#xD;
&#xD;
          -  Known or active central nervous system metastases and/or carcinomatous meningitis&#xD;
&#xD;
          -  Active autoimmune disease that has required systemic treatment in past 2 years (ie,&#xD;
             with use of disease modifying agents, corticosteroids, or immunosuppressive drugs).&#xD;
&#xD;
          -  Evidence of interstitial lung disease or current active, noninfectious pneumonitis&#xD;
&#xD;
          -  Active infection requiring systemic therapy&#xD;
&#xD;
          -  Known or active bacterial, viral, and fungal infection including tuberculosis, active&#xD;
             Hepatitis B (eg, HBsAg reactive), or Hepatitis C (eg, RNA [qualitative] is detected)&#xD;
&#xD;
          -  Known history of testing positive for human immunodeficiency virus (HIV) or acquired&#xD;
             immunodeficiency syndrome (AIDS)-related illness&#xD;
&#xD;
          -  Received a live vaccine within 30 days of study Day 1. Note: seasonal influenza&#xD;
             vaccines for injection are generally inactivated flu vaccines and are allowed; however&#xD;
             intranasal influenza vaccines (eg, Flu-Mist®) are live attenuated vaccines, and are&#xD;
             not allowed.&#xD;
&#xD;
          -  Patients expecting to breastfeed during the study and through 120 days after the last&#xD;
             dose of study treatment&#xD;
&#xD;
          -  Major surgery or significant traumatic injury ≤ 28 days before study day 1, or&#xD;
             anticipation of the need for major surgery during the course of study treatment.&#xD;
&#xD;
          -  Currently participating or participated in a study of an investigational agent and&#xD;
             received study therapy (including RM-1929 or ASP-1929 PIT studies), or used an&#xD;
             investigational device within 4 weeks of study Day 1&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy Mueller</last_name>
    <role>Study Director</role>
    <affiliation>Rakuten Medical, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy Mueller</last_name>
    <phone>858-207-3113</phone>
    <email>clinicaltrialinfo@rakuten-med.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami Hospital and Clinics</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zuzel Rodriguez</last_name>
      <phone>305-243-0124</phone>
      <email>z.rodriguez1@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Francisco Civantos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Howard</last_name>
      <phone>859-323-8749</phone>
      <email>sarah.kamer@uky.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph Valentino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Morris</last_name>
      <phone>503-215-7503</phone>
      <email>george.morris@providence.org</email>
    </contact>
    <investigator>
      <last_name>Bryan Bell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn Poller</last_name>
      <phone>215-955-1964</phone>
      <email>Dawn.poller@Jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>David Cognetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Young</last_name>
      <phone>615-875-2342</phone>
      <email>allison.young@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Michael Gibson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas, MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Leak</last_name>
      <phone>713-563-2107</phone>
      <email>wjleak@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Ann Gillenwater, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 10, 2020</study_first_submitted>
  <study_first_submitted_qc>March 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2020</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rakuten Medical</keyword>
  <keyword>ASP-1929</keyword>
  <keyword>HNSCC</keyword>
  <keyword>CUSCC</keyword>
  <keyword>head and neck</keyword>
  <keyword>cutaneous</keyword>
  <keyword>squamous cell carcinoma</keyword>
  <keyword>photoimmunotherapy</keyword>
  <keyword>PIT</keyword>
  <keyword>skin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Cemiplimab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

